Clinical outcomes of Epstein-Barr virus infection/reactivation following CAR-T cell therapy: A systematic review.
Epstein-Barr virus reactivation after CAR-T cell therapy is an under-recognized safety problem requiring better monitoring as CAR-T treatments expand.
This systematic review characterizes the emerging but poorly defined problem of EBV infection and reactivation following CAR-T cell therapy, identifying it as a clinically significant complication linked to treatment-induced immunosuppression that is currently underrecognized and under-monitored. The limited and heterogeneous evidence base highlights a critical gap in CAR-T safety monitoring protocols, particularly as CAR-T use expands to more diverse hematologic malignancy populations.
What the study was
- Study design
- Systematic review
- Population
- CAR-T cell therapy recipients developing EBV infection or reactivation
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Transplant immunology
Why it surfaced
Systematic review of an underrecognized CAR-T safety complication with clinical management implications; relevant for evolving CAR-T safety monitoring protocols as CAR-T use scales in hematologic malignancies.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.